IL320452A - Combination therapy for prostate cancer - Google Patents
Combination therapy for prostate cancerInfo
- Publication number
- IL320452A IL320452A IL320452A IL32045225A IL320452A IL 320452 A IL320452 A IL 320452A IL 320452 A IL320452 A IL 320452A IL 32045225 A IL32045225 A IL 32045225A IL 320452 A IL320452 A IL 320452A
- Authority
- IL
- Israel
- Prior art keywords
- niraparib
- prednisone
- abiraterone acetate
- patient
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485164P | 2017-04-13 | 2017-04-13 | |
| PCT/US2018/026661 WO2018191141A1 (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320452A true IL320452A (en) | 2025-06-01 |
Family
ID=62067858
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320452A IL320452A (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
| IL269879A IL269879B2 (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL269879A IL269879B2 (en) | 2017-04-13 | 2018-04-09 | Combination therapy for prostate cancer |
Country Status (33)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018023017A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer |
| WO2020139339A1 (en) * | 2018-12-27 | 2020-07-02 | Constellation Pharmaceuticals, Inc. | Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer |
| CN110538150A (zh) | 2019-09-26 | 2019-12-06 | 湖南瑞林医药科技有限公司 | 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用 |
| JP7442328B2 (ja) * | 2020-02-03 | 2024-03-04 | 株式会社三共 | 遊技機 |
| CN113546037B (zh) * | 2020-04-20 | 2024-12-27 | 鲁南制药集团股份有限公司 | 一种醋酸阿比特龙栓剂及其制备方法 |
| JP2023524794A (ja) * | 2020-05-08 | 2023-06-13 | ヤンセン ファーマシューティカ エヌ．ベー． | アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置 |
| EP4313034A1 (en) * | 2021-03-24 | 2024-02-07 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
| CN114306236B (zh) * | 2021-12-15 | 2022-10-21 | 湖南慧泽生物医药科技有限公司 | 用于负载醋酸阿比特龙的自微乳体系及组合物和应用 |
| TWI828471B (zh) | 2021-12-15 | 2024-01-01 | 大陸商湖南慧澤生物醫藥科技有限公司 | 醋酸阿比特龍的自微乳組合物和應用 |
| IL316019A (en) * | 2022-04-07 | 2024-11-01 | Astrazeneca Ab | Combined treatment for cancer |
| WO2024203348A1 (ja) * | 2023-03-31 | 2024-10-03 | ソニーグループ株式会社 | 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法 |
| WO2025027138A1 (en) * | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20130961T1 (hr) * | 2006-08-25 | 2013-11-22 | Janssen Oncology, Inc. | Kombinacije za tretman raka |
| US20080051380A1 (en) * | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| EP2240466B1 (en) | 2008-01-08 | 2015-07-29 | Merck Sharp & Dohme Limited | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| US9314473B2 (en) * | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| WO2014089324A1 (en) * | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
-
2018
- 2018-04-09 EA EA201992430A patent/EA201992430A1/ru unknown
- 2018-04-09 EP EP22200801.3A patent/EP4176878A1/en active Pending
- 2018-04-09 AU AU2018251594A patent/AU2018251594A1/en not_active Abandoned
- 2018-04-09 WO PCT/US2018/026661 patent/WO2018191141A1/en not_active Ceased
- 2018-04-09 HR HRP20221327TT patent/HRP20221327T1/hr unknown
- 2018-04-09 IL IL320452A patent/IL320452A/en unknown
- 2018-04-09 KR KR1020267009381A patent/KR20260048358A/ko active Pending
- 2018-04-09 SM SM20220467T patent/SMT202200467T1/it unknown
- 2018-04-09 LT LTEPPCT/US2018/026661T patent/LT3609497T/lt unknown
- 2018-04-09 ES ES18720895T patent/ES2931052T3/es active Active
- 2018-04-09 CN CN201880039365.1A patent/CN110753545A/zh active Pending
- 2018-04-09 DK DK18720895.4T patent/DK3609497T3/da active
- 2018-04-09 PE PE2019002030A patent/PE20200444A1/es unknown
- 2018-04-09 PL PL18720895.4T patent/PL3609497T3/pl unknown
- 2018-04-09 JO JOJO/P/2019/0244A patent/JOP20190244B1/ar active
- 2018-04-09 MA MA48728A patent/MA48728B1/fr unknown
- 2018-04-09 RS RS20221127A patent/RS63832B1/sr unknown
- 2018-04-09 MX MX2019012296A patent/MX2019012296A/es unknown
- 2018-04-09 EP EP18720895.4A patent/EP3609497B1/en active Active
- 2018-04-09 HU HUE18720895A patent/HUE060460T2/hu unknown
- 2018-04-09 KR KR1020197032257A patent/KR20190134718A/ko not_active Ceased
- 2018-04-09 EP EP22200882.3A patent/EP4176879A1/en not_active Withdrawn
- 2018-04-09 JP JP2019555852A patent/JP7141408B2/ja active Active
- 2018-04-09 SG SG11201909552V patent/SG11201909552VA/en unknown
- 2018-04-09 UA UAA201911057A patent/UA129514C2/uk unknown
- 2018-04-09 CA CA3059562A patent/CA3059562A1/en active Pending
- 2018-04-09 CR CR20190467A patent/CR20190467A/es unknown
- 2018-04-09 CN CN202411589875.XA patent/CN119235874A/zh active Pending
- 2018-04-09 PT PT187208954T patent/PT3609497T/pt unknown
- 2018-04-09 MD MDE20200190T patent/MD3609497T2/ro not_active IP Right Cessation
- 2018-04-09 IL IL269879A patent/IL269879B2/en unknown
- 2018-04-09 MY MYPI2023006196A patent/MY209010A/en unknown
- 2018-04-11 US US15/950,707 patent/US20180296574A1/en active Pending
-
2019
- 2019-10-08 CL CL2019002871A patent/CL2019002871A1/es unknown
- 2019-10-09 NI NI201900105A patent/NI201900105A/es unknown
- 2019-10-10 PH PH12019502317A patent/PH12019502317A1/en unknown
- 2019-10-14 DO DO2019000264A patent/DOP2019000264A/es unknown
- 2019-10-14 MX MX2023009569A patent/MX2023009569A/es unknown
- 2019-10-18 CO CONC2019/0011591A patent/CO2019011591A2/es unknown
-
2022
- 2022-02-25 US US17/680,553 patent/US20220175801A1/en not_active Abandoned
- 2022-07-22 JP JP2022117192A patent/JP7407880B2/ja active Active
-
2023
- 2023-07-13 JO JOJO/P/2023/0159A patent/JOP20230159A1/ar unknown
- 2023-11-20 JP JP2023196574A patent/JP2024023344A/ja active Pending
-
2024
- 2024-02-01 US US18/429,778 patent/US20240245710A1/en active Pending
- 2024-04-11 AU AU2024202346A patent/AU2024202346B2/en active Active
- 2024-08-09 US US18/799,339 patent/US20240398837A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516646A5 (enExample) | ||
| HRP20221327T1 (hr) | Niraparib, abirateron acetat i prednizon za liječenje raka prostate | |
| JP2016540738A5 (enExample) | ||
| JP2019536805A5 (enExample) | ||
| Petrella et al. | Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells | |
| JP2012082215A5 (enExample) | ||
| JP2010501575A5 (enExample) | ||
| BR112018013245A2 (pt) | método e aparelho para administração óxido nítrico com drogas suplementares | |
| EP2460522A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| JP2010501576A5 (enExample) | ||
| TW200501945A (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
| JP2019522032A5 (enExample) | ||
| JP2017516802A5 (enExample) | ||
| WO2005046593A3 (en) | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2021502347A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| RU2005126819A (ru) | Усовершенствованное лечение опухолей | |
| JP2019507786A5 (enExample) | ||
| JP2025511402A5 (enExample) | ||
| JP2025511401A5 (enExample) | ||
| MX2018005876A (es) | Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. | |
| US20260041676A1 (en) | Combination Therapy | |
| JP2019535830A5 (enExample) | ||
| WO2022046452A3 (en) | Nanoparticulate system for delivery of pain relief agents |